Loading clinical trials...
Loading clinical trials...
Phase I Dose-Escalation Study, to Evaluate the Safety, Tolerability and Pharmacokinetics of a Topical Compound 31543 (Calcitriol, USP) in Adult Cancer Patients Receiving Taxane-based Chemotherapy Regimens for the Treatment of Advanced or Recurrent Disease
Conditions
Interventions
Compound 31543 Calcitriol 5 μg/mL
Compound 31543 Calcitriol 10 μg/mL
+4 more
Locations
2
United States
Samuel Oschin Comprehensive Cancer Institute Cedars-Sinai
Los Angeles, California, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Start Date
September 17, 2012
Primary Completion Date
February 16, 2017
Completion Date
February 16, 2017
Last Updated
May 28, 2025
Lead Sponsor
BPGbio
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions